Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Xention spins off Provesica; new company completes Series A round

Executive Summary

Xention Ltd. (ion channel-modulating therapeutics) has spun off newly formed Provesica Ltd. to continue developing XEND0501, Xention's Phase I TRPV1 antagonist for overactive bladder. Provesica is separately owned by Xention's shareholders.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Spin-Off
    • Private Placement

Related Companies

Advertisement
UsernamePublicRestriction

Register